Recombinant Human Udp-Glucuronosyltransferase 1-1 (UGT1A1) Protein (His)

Name: Recombinant Human Udp-Glucuronosyltransferase 1-1 (UGT1A1) Protein (His)
Brand: Beta LifeScience
SKU: BLC-10867P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Udp-Glucuronosyltransferase 1-1 (UGT1A1) Protein (His) is produced by our Yeast expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P22309
Target Symbol	UGT1A1
Synonyms	BILIQTL1; Bilirubin specific UDPGT isozyme 1; bilirubin UDP glucuronosyltransferase 1 1; bilirubin UDP glucuronosyltransferase isozyme 1; Bilirubin-specific UDPGT isozyme 1; EC 2.4.1.17; GNT1; HUG BR1; HUG-BR1; HUGBR1; PHENOL/BILIRUBIN UDP GLUCURONOSYLTRANSFERASE; UD11_HUMAN; UDP glucuronosyltransferase 1 1 [Precursor]; UDP glucuronosyltransferase 1 family polypeptide A1; UDP glucuronosyltransferase 1A1; UDP GLYCOSYLTRANSFERASE 1; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1-A; UDP-glucuronosyltransferase 1A1; UDPGT; UDPGT 1-1; UGT 1A; UGT-1A; UGT1; UGT1 01; UGT1*1; UGT1-01; UGT1.1; UGT1A; Ugt1a1; URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE, BILIRUBIN/PHENOL; URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 1; URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1
Species	Homo sapiens (Human)
Expression System	Yeast
Tag	N-6His
Target Protein Sequence	HAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCPNPFSYVPRPLSSHSDHMTFLQRVKNMLIAFSQNFLCDVVYSPYATLASEFLQREVTVQDLLSSASVWLFRSDFVKDYPRPIMPNMVFVGGINCLHQNPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH
Expression Range	26-533aa
Protein Length	Full Length of Mature Protein
Mol. Weight	59.1kDa
Research Area	Metabolism
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile. Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds. Catalyzes the glucuronidation of endogenous estrogen hormones such as estradiol, estrone and estriol. Involved in the glucuronidation of bilirubin, a degradation product occurring in the normal catabolic pathway that breaks down heme in vertebrates. Also catalyzes the glucuronidation the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties. Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist losartan, a drug which can inhibit the effect of angiotensin II. Involved in the biotransformation of 7-ethyl-10-hydroxycamptothecin (SN-38), the pharmacologically active metabolite of the anticancer drug irinotecan.; Lacks UGT glucuronidation activity but acts as a negative regulator of isoform 1.
Subcellular Location	Endoplasmic reticulum membrane; Single-pass membrane protein. Cytoplasm, perinuclear region.
Protein Families	UDP-glycosyltransferase family
Database References	HGNC: 12530 OMIM: 143500 KEGG: hsa:54658 STRING: 9606.ENSP00000304845 UniGene: PMID: 30237061 On Title. PMID: 29441806 we observed that protein expression of UGT1A1 was significantly more frequent in samples from endometriotic lesions in comparison with endometria. In addition, expression of UGT1A1 protein was greater in deep-infiltrating than in non-deep-infiltrating endometriotic lesions. PMID: 29540112 The suggesting that regulation by other factors could hide the contribution of miR-141-3p to the regulation of UGT1A constitutive expression in the human liver. PMID: 30001838 The UGT1A128 gene variant is associated with lower mortality rates. The protective effect of the UGT1A128 variant likely includes mechanism other than bilirubin metabolism. PMID: 29220881 UGT1A127 can occur separately from UGT1A128 and is related to leukopenia during irinotecan treatment. UGT1A17 is less relevant to irinotecan-induced toxicities, and UGT1A129 seems to have little clinical impact. PMID: 29052349 TLR4 small interfering RNA blocked hUGT1A1/hNRs downregulation. PMID: 29311138 The cancer patients who carried UGT1A16, UGT1A128 and UGT1A160 gene polymorphisms have high risk of severe adverse events caused by irinotecan-based chemotherapy. PMID: 30139029 In terms of irinotecan-based regimens in cancers, UGT1A16 plays a more vital role in hematologic toxicity whereas UGT1A128 get more involved in diarrhea. PMID: 28879724 Heterozygous UGT1A160 4 times (13.3%) and homozygous 26 times (86.7%) in the neonatal hyperbilirubinemia group, with an identical allele frequency of 0.935 in hyperbilirubinemia and 1 in control group. PMID: 29534743 UGT1A1 Genetic Variations and a Haplotype Associated with Neonatal Hyperbilirubinemia in Indonesian Population. PMID: 29607327 The genetic polymorphisms of UGT1A1 were significantly associated with higher plasma axitinib levels in patients with metastatic renal cell carcinoma PMID: 29524031 The findings provide genetic and epidemiological evidence for an association of UGT1A and CCR5 polymorphisms with hepatitis B virus infection in Chinese Yi and Yao populations. PMID: 29239247 Genetic variant minor allele frequencies were similar between cases and controls, except for UGT1A128. PMID: 29210320 During liver ontogeny recruitment of HNF1A leads to aggregation of the cofactors MLL1, NCOA6, and p300 at the UGT1A1 promoter, which regulates histone modifications and subsequent UGT1A1 expression. PMID: 29025858 Patients who initiated atazanavir/ritonavir-containing regimens, UGT1A1 slow metabolizer genotype rs887829 T/T was associated with increased bilirubin-related discontinuation of atazanavir in White but not in Black patients, this despite T/T genotype being more frequent in Black patients. PMID: 29117017 Patients with asthenic constitution and the stigma dysplasia of connective tissue have to be examined by the presence of mutations rs8175347 gene UGT1A1. The carrier not only homozygous but with the heterozygous variant mutations may require changes in the interpretation of symptoms, lifestyle, medication, etc. PMID: 29889392 Results show that the occurrence of neonatal hyperbilirubinemia of neonates was not associated with UGT1A128 gene polymorphism, but closely correlated with the Gly71Arg gene polymorphism. Meanwhile, the Arg allele mutation was related to the degree of jaundice. PMID: 29058288 UGT1A1 gene promoter polymorphism and G71R mutation are possible risk factors for Turkish neonates with DC(-) ABO incompatibility and unexplained hyperbilirubinemia. PMID: 27842454 The presence of the TA7 allele UGT1A1 gene promoter, responsible for higher systemic bilirubin levels, was associated with a twofold lower risk of manifestation of Fabry Disease. PMID: 28951772 results suggested that Gly71Arg and Asn130Asp mutations in UGT1A1 and OATP2 genes might be involved in the development of hyperbilirubinemia in neonates. PMID: 26960716 Genotype TA7/TA7 of the UGT1A1 gene can influence serum bilirubin levels in sickle cell disease. PMID: 28567595 Results still showed UGT1A16 and UGT1A128 to be partially associated with irinotecan-induced toxicity and clinical response. An examination of more UGT1A loci, except for UGT1A16 and UGT1A128, was not helpful to improve the predictive value of irinotecan-based toxicity and efficacy. An examination of DPYD5 assisted in the prediction of severe diarrhea. PMID: 28637434 UGT1A1 polymorphisms have the potential to be a prognostic marker of irinotecan treatment. PMID: 28173214 Although we have found quite a large number of genetic variants of the UGT1A1 and SLCO1B1 genes in the African-American population, it does not appear that they have a significant impact on the incidence of hyperbilirubinemia among this group of infants. PMID: 27977017 it is unclear whether UGT1A1 plays a role in the development of anti-tuberculosis drug-induced hepatotoxicity in the Chinese population PMID: 27155186 The MTD of irinotecan in FOLFIRI plus bevacizumab is 310 mg/m(2) for UGT1A1 1/1 patients and 260 mg/m(2) for 1/28 patients. Bevacizumab does not alter the pharmacokinetics of irinotecan. The antitumor efficacy of these genotype-guided doses should be tested in future studies of patients with mCRC treated with FOLFIRI plus bevacizumab PMID: 27507617 Longer progression-free was seen in breast cancer patients who were heterozygous for a UGT1A1 mutation compared with homozygous wild-type patients when treated with irinotecan combined with S-1. PMID: 29131533 UGT1A16 and/or UGT1A128 alleles are associated with plasma dolutegravir concentrations in Japanese individuals infected with HIV-1. PMID: 28915895 The linked polymorphisms, A(TA)7TAA and c.-3279T>G, in UGT1A1, were most strongly associated with Gilbert syndrome, whereas mutations in the coding region, particularly p.G71R and p.Y486D, occurred more frequently in CNS-II. In addition, iron deposition may be more common in liver biopsies from patients with Crigler-Najjar syndrome type II. PMID: 29137095 UGT1A16 is a risk factor for prolonged unconjugated hyperbilirubinemia in preterm infants in Japan PMID: 28888563 Our findings indicate that regorafenib plus FOLFIRI with irinotecan dose escalation based on UGT1A1 genotyping in previously treated patients with mCRC and with UGT1A11/1 and UGT1A11/28 genotypes is clinically effective and yields improved oncological outcomes. PMID: 27938508 Besides G6PD-deficiency screening, UGT1A1 genetic analysis, and especially the UGT1A16(c.211G>A, p.Arg71Gly) polymorphism detection, may be taken into consideration for early diagnosis and treatment of severe hyperbilirubinemic newborns in southern China. PMID: 26727668 Polymorphisms in SLCO1B1 and UGT1A1 are associated with several different sorafenib side effects PMID: 27533851 Results suggest that in the Romanian population there is a strong correlation between the UGT1A128 polymorphism and hyperbilirubinemia in patients with Gilbert syndrome. PMID: 28338110 Homozygous c-3279T>G mutation represents an important risk factor for the development of neonatal hyperbilirubinemia PMID: 27318112 Polymorphisms of the UGT1A1 gene frequently co-exist in neonates. The presence of UGT1A128 polymorphism and male gender seem to predispose to neonatal hyperbilirubinemia PMID: 28399191 The presence of the UGT1A160 variant is not associated with increased bilirubin concentrations. PMID: 27967321 UGT1A16 polymorphisms were associated with an increased risk of irinotecan-induced neutropenia in cancer patients, and increased incidences of severe neutropenia could be correlated with diverse regions, cancer type, low dose of irinotecan and the duration of treatment PMID: 28585035 UGT1A1 rs6742078 is strongly associated with bilirubin levels; however, a 2-stage least-squares Mendelian randomization analysis shows no causal relationship between serum bilirubin and stroke risk. PMID: 28389615 These data suggest that the UGT1A128 polymorphism may not be a suitable biomarker to predict irinotecan-induced toxicities and chemotherapy tumor response in Asians--{REVIEW] PMID: 28502040 Genetic polymorphisms of the UGT1A1 promoter, specifically the T-3279G phenobarbital-responsive enhancer module and (TA)7 dinucleotide repeat, as well as the intron and coding region variants of the OATP2, HMOX1, and BLVRA genes, were significantly higher among the cases than the controls. PMID: 27943244 UGT1A1 variations have a role in chemotherapy-induced unconjugated hyperbilirubinemia in pediatric leukemia patients PMID: 27057738 UGT1A12828 genotype was significantly associated with lung cancer compared to other malignancies. PMID: 27832386 these results suggest the presence of the UGT1A128 allele does not contribute significantly to a large inter-subject variability in the pharmacokinetics of silybin A and silybin B which may obscure the ability to detect beneficial effects of silymarin in patients with liver disease. PMID: 28098838 UGT1A1 can control neurodevelopment by regulating serum Thyroxine levels. PMID: 27413119 Data suggest that microRNA-375 acts as repressor of UGT1A1- (UDP glucuronosyltransferase 1A1-) mediated hepatic acetaminophen glucuronidation through reduced AhR (aryl hydrocarbon receptor) expression; variations could predispose some individuals to increased risk for acetaminophen-induced liver injury. PMID: 27531059 Cadmium and arsenic override NF-kappaB developmental regulation of the intestinal UGT1A1 gene and control of hyperbilirubinemia. PMID: 27060662 Among patients with increased bilirubin levels, the frequency of UGT1A128 is higher than in those with normal bilirubin. PMID: 28296739 findings showed that almost 57.1% of Chinese colorectal cancer patients had at least one variant of DPYD5A and DPYD9A PMID: 27461651

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

📧 inquiry@betalifesci.com 📞 +1(201) 888-7983

Contact Us Now for Inquiries, Orders, and Questions

Recombinant Human Udp-Glucuronosyltransferase 1-1 (UGT1A1) Protein (His)

Recombinant Human Udp-Glucuronosyltransferase 1-1 (UGT1A1) Protein (His)

Product Overview

Target Details

FAQs